Disease-specific indications

New outcomes data and research has defined which patients can benefit from hematopoietic cell transplant (HCT) and when this therapy is best applied. HCT offers a potential cure for blood cancers, such as leukemia and lymphoma, and other life-threatening diseases.

HCT data trends

Overall volume trends and indications for transplantation show autologous and allogeneic HCT volume, age trends and disease indications for transplant.

This data was prepared by the CIBMTR® (Center for International Blood and Marrow Transplant Research®), a research collaboration between NMDP^SM and the Medical College of Wisconsin.

Outcomes data
Consultation timing data
Post-transplant data

Outcomes and indications by disease

Access current research, outcomes and consultation guidelines & outcomes below to support your clinical decision-making.

Adult leukemia and myelodysplasia

Acute myeloid leukemia (AML)
Acute lymphoblastic leukemia (ALL)
Myelodysplastic syndromes (MDS)
Chronic myeloid leukemia (CML)
Myeloproliferative neoplasms (MPN)
Chronic lymphocytic leukemia (CLL)

Pediatric leukemia and myelodysplasia

Acute myeloid leukemia (AML)
Acute lymphoblastic leukemia (ALL)
Myelodysplastic syndromes (MDS)

Lymphomas

Non-Hodgkin lymphoma (NHL)
Hodgkin lymphoma (HL) 

Plasma cell disorders

Multiple myeloma
Light chain amyloidosis
POEMS syndrome (osteosclerotic myeloma)

Other malignant diseases

Germ cell tumors
Neuroblastoma
Ewing family of tumors
Medulloblastoma

Non-malignant disorders

Immune deficiency diseases
Inherited metabolic disorders
Hemophagocytic lymphohistiocytosis (HLH)
Severe aplastic anemia
Other marrow failure diseases 
Systemic sclerosis (SS)
Multiple Sclerosis (MS)
Sickle cell disease (SCD)
Transfusion-dependent thalassemias